Jonathan T Lei

13PUBLICATIONS
118CO-AUTHORS
Molecular targetsPredictive and prognostic markersProteomics and metabolomicsCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 15, 2026
LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations.

|Aug 27, 2025
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors.

Ze-Yi Zheng, Anran Chen, Eric J Jaehnig

|Dec 23, 2024
Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses.

Jonathan T Lei, Lacey E Dobrolecki, Chen Huang

|May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.

Anran Chen, Beom-Jun Kim, Aparna Mitra

|Aug 17, 2023
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins.

Junkai Wang, Alexander B Saltzman, Eric J Jaehnig

|Jul 28, 2023
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment.

Beom-Jun Kim, Ze-Yi Zheng, Jonathan T Lei

Pageof 3

Frequent Collaborators

8 joint publications

Matthew J Ellis

7 joint publications

Meenakshi Anurag

5 joint publications

Xuxu Gou

5 joint publications

Bora Lim